Enkastins: new glycopeptides which act to inhibit enkephlinase, processes for their preparation, and their use as pharmaceutical products

US5302582A · kind A · utility

Assignee

• Hoechst GmbH · DE

Inventors

• Laszlo Vertesy · Eppstein, DE
• Peter Schindler · Rodgau, DE
• Herbert Kogler · Königstein, DE
• Hans-Wolfram Fehlhaber · Idstein, DE
• Francoise Delevallee · Fontenay-sous-Bois, FR

Key dates

• Filing date: Jul 5, 1991
• Grant date: Apr 12, 1994
• Expiry date: Jul 5, 2011

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12R2001/47
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to new biologically active glycopeptides of the general formula EQU Sacch--A--B--R in which Sacch represents a monosaccharide residue with, where appropriate, the OH groups being partially or completely substituted, PA0 A represents the residue of a neutral L- or D-amino acid or --if B is absent--represents the residue of a neutral D-amino acid, PA0 B is absent or represents the residue of a neutral L- or D-amino acid or of an optionally .omega.-substituted bi-functional acidic or basic L- or D-amino acid, and R represents hydroxyl, (C.sub.1 -C.sub.8)-alkoxy, an amino radical which is optionally substituted by one or two identical or different radicals from the series comprising (C.sub.1 -C.sub.8)-alkyl, (C.sub.5 -C.sub.8)-cycloalkyl, (C.sub.5 -C.sub.8)-heteroalkyl or (C.sub.5 -C.sub.8)-heteroaryl, or another acid derivative. These compounds have enkephalinase-inhibiting properties and can thus be used, for example, as analgesics in human and veterinary medicine. The isolation of these compounds from Streptomyces albus ATCC 21838, and further processes for their preparation, are also described.